Pediatric Febrile Urinary Tract Infection Caused by ESBL Producing Enterobacteriaceae Species
Open Access
- 1 January 2020
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2020 (1)
Abstract
Background. Over the past decade, drug resistance pattern has worsened for many of the uropathogens due to overuse of antibiotics for empiric treatment. The burden of extended spectrum beta‐lactamase (ESBL) producing Enterobacteriaceae associated urinary tract infections (UTI) has become increasingly more common, limiting treatment options among children presenting with febrile UTI. We investigated the burden and correlates of ESBL producing Enterobacteriaceae associated UTI among children and antibacterial resistance pattern. Methods. 284 midstream urine specimens were collected using standard aseptic techniques from 284 children who were diagnosed with suspected UTI. Urine culture and bacteria isolation were performed following standard bacteriological techniques. The Kirby‐Bauer disk diffusion technique and the double‐disc synergy test were used to investigate antibiotic susceptibility and presence of ESBL production. Results. UTI was confirmed using a positive urine culture for a relevant pathogen in 96/284 (33.8%) of the cases. Enterobacteriaceae accounted for 75% (72/96) of etiologies of UTI in children. The most frequent Enterobacteriaceae spp. were E. coli, 44.4% (32/72) and K. pneumonia, 27.8% (20/72). The overall multidrug resistance rate was 86.1% (62/72). ESBL‐producers accounted for 41.7% (30/72) of the isolated Enterobacteriaceae. ESBL producing K. pneumonia and E. coli isolates accounted for 70% (14/20) and 37.5% (12/32), respectively. History of UTI in the past 1 year (adjusted odds ratio (AoR) = 0.08, 95%CI (0.01 − 0.57)) and medium family wealth index (AoR = 0.03, 95%CI (0.00 − 0.27)) protected from infection with ESBL‐producing Enterobacteriaceae. Conclusion. ESBL production was more common in K. pneumonia and appeared to be a major factor contributing drug resistance UTI in children. The findings call for the need to incorporate ESBL testing in the routine clinical practice. The resistance level to commonly prescribed first‐line antibiotics observed within Enterobacteriaceae was alarming calling for strengthened antimicrobial stewardship.Keywords
Funding Information
- Hawassa University
This publication has 20 references indexed in Scilit:
- Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest EthiopiaAntimicrobial Resistance & Infection Control, 2015
- Antimicrobial susceptibility of urinary Klebsiella pneumoniae and the emergence of carbapenem-resistant strains: A retrospective study from a university hospital in Morocco, North AfricaAfrican Journal of Urology, 2015
- Extended Spectrum Beta-Lactamases in Clinical Isolates of Escherichia coli and Klebsiella pneumoniae from University of Uyo Teaching Hospital, Uyo-NigeriaJournal of Advances in Medical and Pharmaceutical Sciences, 2015
- Urinary tract infections caused by extended-spectrum betalactamase-producing bacteria in children: a matched casecontrol studyThe Turkish Journal of Pediatrics, 2013
- Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, NepalBMC Research Notes, 2013
- Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency DepartmentEmergency Medicine International, 2013
- Extended-Spectrum Beta-Lactamase InfectionsCurrent Emergency and Hospital Medicine Reports, 2013
- Frequency of extended spectrum beta lactamase producing enterobacteriaceae among urinary pathogen isolates.2011
- Decreased Susceptibility to Commonly Used Antimicrobial Agents in Bacterial Pathogens Isolated from Urinary Tract Infections in Rwanda: Need for New Antimicrobial GuidelinesThe American Journal of Tropical Medicine and Hygiene, 2011
- Extended Spectrum ??-Lactamase (ESBL)-Producing EnterobacteriaceaeDrugs, 2003